Redalpine exited its stake in Medmira Holding AG.

MedMira improves human health with its point-of-care diagnostics tests based on its proprietary Rapid Vertical Flow TechnologyTM platform. MedMira’s tests detect infectious diseases such as HIV, Hepatitis, and Syphilis with only one drop of specimen. The platform offers unique advantages – in just 2–3 minutes the tests deliver FDA-grade results, independent of any lab infrastructure. In addition, several diseases can be detected in the same cartridge simultaneously (multiplexing).